NASDAQ:RETA - Reata Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$86.76 -0.38 (-0.44 %)
(As of 03/25/2019 10:30 AM ET)
Previous Close$87.13
Today's Range$85.02 - $87.13
52-Week Range$19.31 - $104.53
Volume73,505 shs
Average Volume279,618 shs
Market Capitalization$2.58 billion
P/E Ratio-30.23
Dividend YieldN/A
Beta3.17
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease. It is also developing omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.

Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.59 million
Book Value$0.51 per share

Profitability

Net Income$-80,550,000.00
Net Margins-150.30%

Miscellaneous

EmployeesN/A
Market Cap$2.58 billion
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals Inc (NASDAQ:RETA) issued its quarterly earnings results on Thursday, February, 28th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.16. The business earned $8.45 million during the quarter, compared to analysts' expectations of $6.60 million. View Reata Pharmaceuticals' Earnings History.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Reata Pharmaceuticals.

What price target have analysts set for RETA?

6 analysts have issued twelve-month price objectives for Reata Pharmaceuticals' stock. Their forecasts range from $92.00 to $139.00. On average, they expect Reata Pharmaceuticals' share price to reach $111.80 in the next year. This suggests a possible upside of 31.2% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals.

What is the consensus analysts' recommendation for Reata Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals.

What are Wall Street analysts saying about Reata Pharmaceuticals stock?

Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 PT on RETA. Reata reported 4Q18 financial performance including collaboration revs of $7.9M, total expenses of $130.5M and cash of $338M. We project current cash to be sufficient to fund operations through 2020, including the three ongoing pivotal trials of bardoxalone in Alport syndrome and CTD-PAH, and omaveloxolone in Friedreich’s ataxia. We see 2019 as a potentially transformational year for the company, with two pivotal trial readouts in the second half and increasing visibility on a broadening set of bard’ indications going forward to further drive shares." (2/28/2019)
  • 2. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (11/28/2018)

Has Reata Pharmaceuticals been receiving favorable news coverage?

Media stories about RETA stock have trended positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Reata Pharmaceuticals earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of Reata Pharmaceuticals' key competitors?

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Celgene (CELG), Progenics Pharmaceuticals (PGNX), CVS Health (CVS), Sorrento Therapeutics (SRNE), Verastem (VSTM), Adamis Pharmaceuticals (ADMP), Synlogic (SYBX), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the folowing people:
  • Mr. J. Warren Huff, Chairman, CEO & Pres (Age 65)
  • Dr. Colin J. Meyer, Chief Medical Officer & VP of Product Devel. (Age 40)
  • Dr. Keith W. Ward, VP & Chief Devel. Officer (Age 49)
  • Mr. Jason D. Wilson, CFO & VP of Strategy (Age 49)
  • Ms. Elaine Castellanos, VP of Fin. & Accounting and Principal Accounting Officer

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.59%), Emerald Mutual Fund Advisers Trust (1.64%), Emerald Advisers LLC (1.58%), FMR LLC (1.03%), Prosight Management LP (0.85%) and Northern Trust Corp (0.77%). Company insiders that own Reata Pharmaceuticals stock include A/S Novo, Abbvie Inc, Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, Jason Douglas Wilson, Keith Wayne Ward and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.

Which institutional investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Columbus Circle Investors, LBJ Family Wealth Advisors Ltd., Virtus ETF Advisers LLC, Bank of New York Mellon Corp, MetLife Investment Advisors LLC, Northern Trust Corp and Cutler Group LP. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Edward Bass, Jason Douglas Wilson and Keith Wayne Ward. View Insider Buying and Selling for Reata Pharmaceuticals.

Which institutional investors are buying Reata Pharmaceuticals stock?

RETA stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, Sofinnova Investments Inc., Sphera Funds Management LTD., Bank of America Corp DE, First Trust Advisors LP, Emerald Mutual Fund Advisers Trust, Millennium Management LLC and BlackRock Inc.. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass, James W Traweek Jr and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $85.19.

How big of a company is Reata Pharmaceuticals?

Reata Pharmaceuticals has a market capitalization of $2.54 billion and generates $53.59 million in revenue each year. The company earns $-80,550,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is http://www.reatapharma.com.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]


MarketBeat Community Rating for Reata Pharmaceuticals (NASDAQ RETA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  420
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Featured Article: What causes a recession?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel